Cleveland HeartLab Launches "it"
Cleveland, Ohio- April 11, 2012- Cleveland HeartLab Inc. (CHL), today announced the launch of a campaign to educate patients and health care professionals about the importance of “it,” or inflammation testing, in determining heart attack and stroke risk. A unique inflammation biomarker panel is at the heart of CHL’s advanced approach to cardiovascular disease risk assessment. “Our new ‘it’ campaign is designed to engage patients about the benefits of inflammation testing and its role in advanced cardiovascular risk assessment like they’ve never been before,” said Marc S. Penn, M.D., Ph.D., F.A.C.C., chief medical officer of Cleveland HeartLab and director of research, Summa Cardiovascular Institute, Akron, Ohio.
For the complete story click here.